Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599686 | 0.93 | HIF1A (0.43) | HIF1AKMT2ASMN1; SMN2L3MBTL1ERCC5 | |
| SCHEMBL23971986 | 0.93 | HIF1A (0.43) | HIF1ARXFP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL25599750 | 0.90 | HIF1A (0.34) | HIF1ARXFP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL23972049 | 0.86 | HIF1A (0.43) | HIF1AKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25599676 | 0.83 | HIF1A (0.34) | HIF1AKMT2ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL23971982 | 0.83 | HIF1A (0.34) | HIF1ARXFP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL23971794 | 0.82 | HIF1A (0.43) | HIF1AALDH1A1LMNAKCNK3KCNK9 | |
| SCHEMBL23972055 | 0.82 | HIF1A (0.48) | HIF1AKMT2AMEN1L3MBTL1ERCC5 | |
| SCHEMBL23971769 | 0.81 | HIF1A (0.45) | HIF1ARXFP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL23979019 | 0.81 | HIF1A (0.43) | HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172206-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS II | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172206-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS II | COX5B, SQOR, UQCRB | HIF1A 2078/4885RXFP1 4291/4885KMT2A 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.